Publication and Abstract Index Utilizing MOSTM Technology
Micro-Organospheres (MOSTM) retain patient tumor microenvironment for precision immuno-oncology
Patient-derived micro-organospheres enable clinical precision oncology
A Micro-organosphere Potency Assay for Adoptive T Cell Therapy
Patient-derived micro-organospheres (MOSTM) recapitulate tumor microenvironment and heterogeneity for precision oncology.
Other Cancers
As the second most common cause of death in the United States, cancer has placed a significant socioeconomic burden on the healthcare system. There is an estimated 1.9 million new cases of cancer and over 600,000 deaths linked to cancer.1 Xilis is developing its MicroOrganoSphereTM platform, which recapitulates the tumor microenvironment and cancer heterogeneity, for precision oncology and the evaluation of chemotherapy and immunotherapy research applications.
American Cancer Society: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html
Accessed September 2021.